An overview of quinoline as a privileged scaffold in cancer drug discovery

Liposomal irinotecan in gemcitabine-refractory metastatic pancreatic cancer: efficacy, safety and place in therapy

(2017) Emma Kipps et al.   Therapeutic Advances in Medical Oncology

Lenvatinib: Role in thyroid cancer and other solid tumors

(2016) Maria E. Cabanillas et al.   CANCER TREATMENT REVIEWS

8-Hydroxyquinolines in medicinal chemistry: A structural perspective

(2016) Valentina Oliveri et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Time to use a dose of Chloroquine as an adjuvant to anti-cancer chemotherapies

(2016) Steve Pascolo   EUROPEAN JOURNAL OF PHARMACOLOGY

Therapeutic significance of quinolines: a patent review (2013-2015)

(2016) Syed Mohammed Ali Hussaini   EXPERT OPINION ON THERAPEUTIC PATENTS

Lenvatinib: a potential breakthrough in advanced hepatocellular carcinoma?

(2016) Georgios Oikonomopoulos et al.   Future Oncology

Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial

(2016) Koichi Goto et al.   LANCET ONCOLOGY

Characterization of LY3023414, a Novel PI3K/mTOR Dual Inhibitor Eliciting Transient Target Modulation to Impede Tumor Growth

(2016) M. C. Smith et al.   MOLECULAR CANCER THERAPEUTICS

Comprehensive review on current developments of quinoline-based anticancer agents

(2016) Shweta Jain et al.   Arabian Journal of Chemistry

Chronic Lymphocytic Leukemia: Exploiting Vulnerabilities with Targeted Agents

(2016) Joseph Maly et al.   Current Hematologic Malignancy Reports

Lenvatinib – A multikinase inhibitor for radioiodine-refractory differentiated thyroid cancer

(2016) Yvonne Hewett et al.   JOURNAL OF ONCOLOGY PHARMACY PRACTICE

A review of topotecan in combination chemotherapy for advanced cervical cancer

(2016) Charles Dunton   Therapeutics and Clinical Risk Management

A Review on the Synthesis and Anti-cancer Activity of 2-substituted Quinolines

(2015) Kaalin Gopaul et al.   Anti-Cancer Agents in Medicinal Chemistry

Cabozantinib for the treatment of non-small cell lung cancer with KIF5B-RET fusion. An example of swift repositioning

(2015) Minsoo Song et al.   ARCHIVES OF PHARMACAL RESEARCH

Quinoline-based antimalarial hybrid compounds

(2015) Stéphanie Vandekerckhove et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Integrative population pharmacokinetic and pharmacodynamic dose finding approach of the new camptothecin compound namitecan (ST1968)

(2015) M. Joerger et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

First-in-Human Phase I Study of GSK2126458, an Oral Pan-Class I Phosphatidylinositol-3-Kinase Inhibitor, in Patients with Advanced Solid Tumor Malignancies

(2015) P. Munster et al.   CLINICAL CANCER RESEARCH

Irreversible Multitargeted ErbB Family Inhibitors for Therapy of Lung and Breast Cancer

(2015) Deepa Subramaniam et al.   CURRENT CANCER DRUG TARGETS

A review on anticancer potential of bioactive heterocycle quinoline

(2015) Obaid Afzal et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Current role of cabozantinib in metastatic castration-resistant prostate cancer

(2015) André P Fay et al.   Expert Review of Anticancer Therapy

A phase 1 study of the sachet formulation of the oral dual PI3K/mTOR inhibitor BEZ235 given twice daily (BID) in patients with advanced solid tumors

(2015) Johanna C. Bendell et al.   INVESTIGATIONAL NEW DRUGS

Phase-I dose finding and pharmacokinetic study of the novel hydrophilic camptothecin ST-1968 (namitecan) in patients with solid tumors

(2015) M. Joerger et al.   INVESTIGATIONAL NEW DRUGS

Investigating Pharmacological Similarity by Charting Chemical Space

(2015) Rosa Buonfiglio et al.   Journal of Chemical Information and Modeling

Quantification of the impact of enzyme-inducing antiepileptic drugs on irinotecan pharmacokinetics and SN-38 exposure

(2015) Alexander K. Berg et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Perspectives on Biologically Active Camptothecin Derivatives

(2015) Ying-Qian Liu et al.   MEDICINAL RESEARCH REVIEWS

P7170: A Novel Molecule with Unique Profile of mTORC1/C2 and Activin Receptor-like Kinase 1 Inhibition Leading to Antitumor and Antiangiogenic Activity

(2015) A. Jalota-Badhwar et al.   MOLECULAR CANCER THERAPEUTICS

8-Hydroxyquinoline: a privileged structure with a broad-ranging pharmacological potential

(2015) Yu'ning Song et al.   MedChemComm

Tivozanib: Status of Development

(2015) Muhammad Omer Jamil et al.   Current Oncology Reports

Cabozantinib for the treatment of progressive metastatic medullary thyroid cancer

(2015) Jolanta Krajewska et al.   Expert Review of Clinical Pharmacology

The casein kinase 2 inhibitor, CX-4945, as an anti-cancer drug in treatment of human hematological malignancies

(2015) Hae J. Chon et al.   Frontiers in Pharmacology

Design, Synthesis and In Vitro Activity of Anticancer Styrylquinolines. The p53 Independent Mechanism of Action

(2015) Anna Mrozek-Wilczkiewicz et al.   PLoS One

The Dual PI3K/mTOR Inhibitor NVP-BEZ235 Is a Potent Inhibitor of ATM- and DNA-PKCs-Mediated DNA Damage Responses

(2015) Bipasha Mukherjee et al.   NEOPLASIA

Bosutinib

(2014) Lindsay Stansfield et al.   ANNALS OF PHARMACOTHERAPY

A Novel Multiple Tyrosine-kinase Targeted Agent to Explore the Future Perspectives of Anti-Angiogenic Therapy for the Treatment of Multiple Solid Tumors: Cabozantinib

(2014) Subhajit Roy et al.   Anti-Cancer Agents in Medicinal Chemistry

Bosutinib: A Review of Its Use in Patients with Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia

(2014) Yahiya Y. Syed et al.   BIODRUGS

Quinoline: A promising antitubercular target

(2014) Rangappa S. Keri et al.   BIOMEDICINE & PHARMACOTHERAPY

HER2-positive gastric cancer with concomitant MET and/or EGFR overexpression: A distinct subset of patients for dual inhibition therapy

(2014) Sang Yun Ha et al.   INTERNATIONAL JOURNAL OF CANCER

Current clinical regulation of PI3K/PTEN/Akt/mTOR signalling in treatment of human cancer

(2014) Hui Jun Lim et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

The Efficacy and Toxicity of Belotecan (CKD-602), A Camptothecin Analogue Topoisomerase I Inhibitor, in Patients with Recurrent or Refractory Epithelial Ovarian Cancer

(2014) Yong-Man Kim et al.   JOURNAL OF CHEMOTHERAPY

Quinoline – a Promising Fragment in the Search for New Antimalarials

(2014) Beata Gryzło et al.   MINI-REVIEWS IN MEDICINAL CHEMISTRY

An Overview on the Development of New Potentially Active Camptothecin Analogs Against Cancer

(2014) Eliza Chazin et al.   MINI-REVIEWS IN MEDICINAL CHEMISTRY

P7170, a novel inhibitor of mTORC1/mTORC2 and Activin receptor-like Kinase 1 (ALK1) inhibits the growth of non small cell lung cancer

(2014) Venkatasubbaiah A Venkatesha et al.   Molecular Cancer

Pharmacokinetic evaluation of the anticancer prodrug simmitecan in different experimental animals

(2013) Zhe-yi Hu et al.   ACTA PHARMACOLOGICA SINICA

Chloroquine in Cancer Therapy: A Double-Edged Sword of Autophagy

(2013) T. Kimura et al.   CANCER RESEARCH

Medicinal Chemistry of Quinolines As Emerging Anti-inflammatory Agents: An Overview

(2013) S. Mukherjee et al.   CURRENT MEDICINAL CHEMISTRY

Quinoline-based HIV Integrase Inhibitors

(2013) Robert Musiol   CURRENT PHARMACEUTICAL DESIGN

Evolution in medicinal chemistry of E-ring-modified Camptothecin analogs as anticancer agents

(2013) Qingqing Huang et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Quinoline- and isoquinoline-sulfonamide analogs of aripiprazole: novel antipsychotic agents?

(2013) Pawel Zajdel et al.   Future Medicinal Chemistry

Tivozanib reverses multidrug resistance mediated by ABCB1 (P-glycoprotein) and ABCG2 (BCRP)

(2013) Danwen Yang et al.   Future Oncology

A phase 1 open-label, sequential dose-escalation study investigating the safety, tolerability, and pharmacokinetics of intravenous TLC388 administered to patients with advanced solid tumors

(2013) Sharad Ghamande et al.   INVESTIGATIONAL NEW DRUGS

Tivozanib Versus Sorafenib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma: Results From a Phase III Trial

(2013) Robert J. Motzer et al.   JOURNAL OF CLINICAL ONCOLOGY

Response of Children with Stage IV Soft Tissue Sarcoma to Topotecan and Carboplatin: A Phase II Window Trial of the Cooperative Soft Tissue Sarcoma Group

(2013) K. Bochennek et al.   KLINISCHE PADIATRIE

Carboplatin +/− Topotecan Ophthalmic Artery Chemosurgery for Intraocular Retinoblastoma

(2013) Jasmine H. Francis et al.   PLoS One

Profile of tivozanib and its potential for the treatment of advanced renal cell carcinoma

(2013) Lance Cowey   Drug Design Development and Therapy

Treatment of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

(2013) A. K. Fielding et al.   Current Hematologic Malignancy Reports

Amsacrine as a Topoisomerase II Poison: Importance of Drug–DNA Interactions

(2012) Adam C. Ketron et al.   BIOCHEMISTRY

Preclinical evaluation of the novel 7-substituted camptothecin Namitecan (ST1968) in paediatric tumour models

(2012) Daniela Meco et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Abstract 4245: Preclinical study of puquitinib, a novel orally available PI3K inhibitor in phase I clinical trials

(2012) Chengying Xie et al.   CANCER RESEARCH

Pharmacokinetics and Antitumor Efficacy of XMT-1001, a Novel, Polymeric Topoisomerase I Inhibitor, in Mice Bearing HT-29 Human Colon Carcinoma Xenografts

(2012) M. D. Walsh et al.   CLINICAL CANCER RESEARCH

Namitecan: a Hydrophilic Camptothecin with a Promising Preclinical Profile

(2012) G. L. Beretta et al.   CURRENT MEDICINAL CHEMISTRY

Privileged Structures - Dream or Reality: Preferential Organization of Azanaphthalene Scaffold

(2012) J. Polanski et al.   CURRENT MEDICINAL CHEMISTRY

Quinolines: a new hope against inflammation

(2012) Soumita Mukherjee et al.   DRUG DISCOVERY TODAY

Understanding the Role of MET Kinase in Cancer Therapy

(2012) Edwin M. Posadas et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II and Biomarker Study of the Dual MET/VEGFR2 Inhibitor Foretinib in Patients With Papillary Renal Cell Carcinoma

(2012) Toni K. Choueiri et al.   JOURNAL OF CLINICAL ONCOLOGY

A phase II trial of oral gimatecan for recurrent glioblastoma

(2012) Jethro Hu et al.   JOURNAL OF NEURO-ONCOLOGY

Sensitivity of Selected Human Tumor Models to PF-04217903, a Novel Selective c-Met Kinase Inhibitor

(2012) H. Y. Zou et al.   MOLECULAR CANCER THERAPEUTICS

A Fluorescent Styrylquinoline with Combined Therapeutic and Diagnostic Activities against Alzheimer’s and Prion Diseases

(2012) Matteo Staderini et al.   ACS Medicinal Chemistry Letters

The role of phosphatidylinositol 3-kinase-  in the immunomodulatory effects of lenalidomide in chronic lymphocytic leukemia

(2011) S. E. M. Herman et al.   BLOOD

Phylogenomics of phosphoinositide lipid kinases: perspectives on the evolution of second messenger signaling and drug discovery

(2011) James R Brown et al.   BMC EVOLUTIONARY BIOLOGY

Mechanism of action of the multikinase inhibitor Foretinib

(2011) Maeva Dufies et al.   CELL CYCLE

Genz-644282, a Novel Non-Camptothecin Topoisomerase I Inhibitor for Cancer Treatment

(2011) L. S. Kurtzberg et al.   CLINICAL CANCER RESEARCH

Dual Inhibitors of PI3K/mTOR or mTOR-Selective Inhibitors: Which Way Shall We Go?

(2011) D. A. Sabbah et al.   CURRENT MEDICINAL CHEMISTRY

Quinoline as a Privileged Scaffold in Cancer Drug Discovery

(2011) V. R. Solomon et al.   CURRENT MEDICINAL CHEMISTRY

ATP Site-Directed Inhibitors of Protein Kinase CK2: An Update

(2011) S. Sarno et al.   CURRENT TOPICS IN MEDICINAL CHEMISTRY

The concept of privileged structures in rational drug design: focus on acridine and quinoline scaffolds in neurodegenerative and protozoan diseases

(2011) Salvatore Bongarzone et al.   Expert Opinion on Drug Discovery

Preclinical and clinical activity of the topoisomerase I inhibitor, karenitecin, in melanoma

(2011) Pamela N Munster et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Novel EGFR-TK Inhibitor EKB-569 Inhibits Hepatocellular Carcinoma Cell Proliferation by AKT and MAPK Pathways

(2011) Heesue Kim et al.   JOURNAL OF KOREAN MEDICAL SCIENCE

Pharmacokinetics of SN2310, an Injectable Emulsion that Incorporates a New Derivative of SN-38 in Patients with Advanced solid Tumors

(2011) Jean-Francois Marier et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

Pre-clinical characterization of CX-4945, a potent and selective small molecule inhibitor of CK2 for the treatment of cancer

(2011) Fabrice Pierre et al.   MOLECULAR AND CELLULAR BIOCHEMISTRY

New Topoisomerase I mutations are associated with resistance to camptothecin

(2011) Céline Gongora et al.   Molecular Cancer

Molecular and Cellular Pharmacology of the Novel Noncamptothecin Topoisomerase I Inhibitor Genz-644282

(2011) D. Sooryakumar et al.   MOLECULAR CANCER THERAPEUTICS

Molecular pathology of tumor-initiating cells: Lessons from Philadelphia chromosome-positive leukemia

(2011) Kazuhito Naka et al.   PATHOLOGY INTERNATIONAL

Testing of the topoisomerase 1 inhibitor Genz-644282 by the pediatric preclinical testing program

(2011) Peter J. Houghton et al.   PEDIATRIC BLOOD & CANCER

An overview of the c-MET signaling pathway

(2011) Shawna Leslie Organ et al.   Therapeutic Advances in Medical Oncology

DNA Topoisomerases and Their Poisoning by Anticancer and Antibacterial Drugs

(2010) Yves Pommier et al.   CHEMISTRY & BIOLOGY

A Phase I Study of 7-t-Butyldimethylsilyl-10-Hydroxycamptothecin in Adult Patients with Refractory or Metastatic Solid Malignancies

(2010) S. M. Arnold et al.   CLINICAL CANCER RESEARCH

Quinoline-Based Antifungals

(2010) R. Musiol et al.   CURRENT MEDICINAL CHEMISTRY

Privileged scaffolds for library design and drug discovery

(2010) Matthew E Welsch et al.   CURRENT OPINION IN CHEMICAL BIOLOGY

Bosutinib: A review of preclinical studies in chronic myelogenous leukaemia

(2010) Frank Boschelli et al.   EUROPEAN JOURNAL OF CANCER

MIA–QSAR coupled to principal component analysis-adaptive neuro-fuzzy inference systems (PCA–ANFIS) for the modeling of the anti-HIV reverse transcriptase activities of TIBO derivatives

(2010) Mohammad Goodarzi et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Advanced Ovarian Cancer: Phase III Randomized Study of Sequential Cisplatin–Topotecan and Carboplatin–Paclitaxel vs Carboplatin–Paclitaxel

(2010) P. Hoskins et al.   JNCI-Journal of the National Cancer Institute

Cancer Therapies Utilizing the Camptothecins: A Review of thein VivoLiterature

(2010) Vincent J. Venditto et al.   MOLECULAR PHARMACEUTICS

The rate of growth in scientific publication and the decline in coverage provided by Science Citation Index

(2010) Peder Olesen Larsen et al.   SCIENTOMETRICS

Drawing the PDB: Protein−Ligand Complexes in Two Dimensions

(2010) Katrin Stierand et al.   ACS Medicinal Chemistry Letters

Design and development of IT-101, a cyclodextrin-containing polymer conjugate of camptothecin

(2009) Mark E. Davis   ADVANCED DRUG DELIVERY REVIEWS

XMT-1001, a novel polymeric camptothecin pro-drug in clinical development for patients with advanced cancer

(2009) Alexander V. Yurkovetskiy et al.   ADVANCED DRUG DELIVERY REVIEWS

Potentiation of a Topoisomerase I Inhibitor, Karenitecin, by the Histone Deacetylase Inhibitor Valproic Acid in Melanoma: Translational and Phase I/II Clinical Trial

(2009) A. I. Daud et al.   CLINICAL CANCER RESEARCH

Neratinib: an oral, irreversible dual EGFR/HER2 inhibitor for breast and non-small cell lung cancer

(2009) Prithviraj Bose et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Novel camptothecin derivatives as topoisomerase I inhibitors

(2009) Serena Basili et al.   EXPERT OPINION ON THERAPEUTIC PATENTS

Fuzzy ARTMAP Prediction of Biological Activities for Potential HIV-1 Protease Inhibitors Using a Small Molecular Data Set

(2009) Razvan Andonie et al.   IEEE-ACM Transactions on Computational Biology and Bioinformatics

Metal ionophores – An emerging class of anticancer drugs

(2009) Wei-Qun Ding et al.   IUBMB LIFE

Targeting the phosphoinositide 3-kinase pathway in cancer

(2009) Pixu Liu et al.   NATURE REVIEWS DRUG DISCOVERY

Synthesis and pharmacological investigation of novel 2-aminothiazole-privileged aporphines

(2008) Zhili Liu et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Diflomotecan, a promising homocamptothecin for cancer therapy

(2008) Judith R Kroep et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Plasma and tissue disposition of non-liposomal DB-67 and liposomal DB-67 in C.B-17 SCID mice

(2008) William C. Zamboni et al.   INVESTIGATIONAL NEW DRUGS

Preclinical profile of antitumor activity of a novel hydrophilic camptothecin, ST1968

(2008) C. Pisano et al.   MOLECULAR CANCER THERAPEUTICS

Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity

(2008) S.-M. Maira et al.   MOLECULAR CANCER THERAPEUTICS

The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP

(2008) C.-H. Yun et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Phase II multicenter open-label study of karenitecin in previously treated epithelial ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study

(2007) J.J. KAVANAGH et al.   INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER